Windows for AI Debt, IPOs & Data Center Permits Appear to Be Closing
Here are three areas that could spell trouble for 2027,
Mid-Cap Biopharma Stock Offers Intriguing Options Trade Amid Market Selloff
With the recent decline, the shares appear at least reasonably valued, and I can make them cheaper and more attractive with the following covered call trade.